首页>投融资
邦耀生物
B+轮
上海邦耀生物科技有限公司是一家以生物技术研发为主的高新技术企业,致力于利用CRISPR/Cas9基因编辑技术来进行肿瘤和遗传疾病治疗的相关研究,并转化成为临床治疗方案,现已产生了一系列相关成果和专利。此外,邦耀生物还具有成熟的新药研发平台,以此开发并获得了20余项小分子化合物专利。依托于该体系,邦耀生物服务于生命科学和药物研发领域,为广大临床研究和基础研究客户提供整体动物、细胞生物学、分子生物学及毒理药理实验等专业技术支持。
基本信息
-
公司全称上海邦耀生物科技有限公司
-
类型基因编辑与细胞治疗技术研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址上海市闵行区元江路3699号14幢一层
-
联系电话021-64340008
-
邮箱fyliu@brlmed.com
-
成立时间2013-09-10
投融资
-
2024-11-22B+轮2亿人民币贝加资本
-
2022-11-14B轮2亿人民币天士力资本贝达基金东方富海歌斐资产自贸区基金
-
2022-11-14B轮2亿人民币东方富海天士力资本贝达基金歌斐资产上海自贸区基金
-
2021-05-19PreB轮未透露歌斐资产
-
2021-01-20A+轮8000万人民币东方富海烟台正基投资合伙企业(有限合伙)上海通锐投资
-
2020-03-01A轮5000万人民币烟台正基投资合伙企业(有限合伙)上海通锐投资安诚资本
-
2018-06-14PreA轮6440万人民币英智云创投资华润资本烟台正基投资合伙企业(有限合伙)
-
2016-06-21A轮未透露东方富海
-
2016-06-21天使轮1313.33万人民币烟台正基投资合伙企业(有限合伙)德宝股权投资玛戈隆特小苗朗程上海通锐投资东方富海
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,